A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Clozaril Patient, Information, Instructions - Clozapine
Clozaril Patient, Information, Instructions - Clozapine
PATIENT
INFORMATION
Physicians are advised to discuss the following issues with
patients for whom they prescribe CLOZARIL:
– Patients who are to receive CLOZARIL should be warned
about the significant risk of developing agranulocytosis. They should be informed
that weekly blood tests are required for the first 6 months, if acceptable WBC
counts (WBC ³ 3000/mm3, ANC ³
1500/mm3) have been maintained during the first 6 months of continuous
therapy, then WBC counts can be monitored every other week in order to monitor
for the occurrence of agranulocytosis, and that CLOZARIL tablets will be made
available only through a special program designed to ensure the required blood
monitoring. Patients should be advised to report immediately the appearance
of lethargy, weakness, fever, sore throat, malaise, mucous membrane ulceration
or other possible signs of infection.
Particular attention should be paid to any flu-like complaints
or other symptoms that might suggest infection.
– Patients should be informed of the significant risk of
seizure during CLOZARIL treatment, and they should be advised to avoid driving
and any other potentially hazardous activity while taking CLOZARIL.
– Patients should be advised of the risk of orthostatic
hypotension, especially during the period of initial dose titration.
– Patients should be informed that if they stop taking CLOZARIL
for more than 2 days, they should not restart their medication at the same dosage,
but should contact their physician for dosing instructions.
– Patients should notify their physician if they are taking,
or plan to take, any prescription or over-the-counter drugs or alcohol.
– Patients should notify their physician if they become
pregnant or intend to become pregnant during therapy.
– Patients should not breast-feed an infant if they are
taking CLOZARIL.
top
